Navigation Links
KCNQ2 Cure Alliance Extends Collaboration With Pairnomix To Provide Genetic Evaluation Services For Patients With Rare Genetic Epileptic Encephalopathy
Date:7/20/2017

DENVER and PLYMOUTH, Minn., July 20, 2017 /PRNewswire/ -- KCNQ2 Cure Alliance and Pairnomix, LLC, a personalized genetic evaluations company, today announced that they have completed the first case under their partnership investigating a genetic mutation implicated in KCNQ2 epileptic encephalopathy. They also report plans to extend the partnership for a second case involving an additional KCNQ2 genetic mutation.

Last year, the KCNQ2 Cure Alliance and Pairnomix entered into a collaboration to further explore genetic mutations in KCNQ2 epileptic encephalopathy with the goal of identifying more effective and more accurately targeted drug therapies. It is estimated that 500 people worldwide have been diagnosed with KCNQ2 epileptic encephalopathy. However, many more are believed to be affected by this rare genetic mutation, but have not been diagnosed due to its relatively recent discovery and availability of genetic testing.

At the end of this first case evaluation, Pairnomix identified through cellular testing a series of drugs capable of inhibiting a gain-of-function KCNQ2 mutation. These drugs represent novel therapeutic options for the consideration of healthcare providers.

"We appreciate the thorough approach Pairnomix undertook while evaluating our first case together and we are excited to see the real-world application from this data," said Jim Johnson, President of KCNQ2 Cure Alliance.

"The KCNQ2 Cure Alliance is a truly caring and supportive organization. We feel privileged to provide our services in an effort to support their community," said Matthew Fox, CEO of Pairnomix.

Clinical evaluation of the top drug result is currently underway and the genetic evaluation of the second case has recently been initiated. Pairnomix and the KCNQ2 Cure Alliance will present data from the initial case at scientific conferences later this year including the annual meetings for Child Neurology Society (CNS), Society for Neuroscience (SfN), and American Epilepsy Society (AES).

About KCNQ2 Epileptic Encephalopathy
KCNQ2 epileptic encephalopathies are caused by mutations in the KCNQ2 gene (also known as the potassium voltage-gated channel, KQT-like subfamily, member 2 gene). KCNQ2 belongs to a large family of genes that provide instructions for making potassium channels. These channels, which transport positively charged atoms (ions) of potassium into and out of cells, play a key role in a cell's ability to generate and transmit electrical signals. Channels made with the KCNQ2 protein are active in nerve cells (neurons) in the brain, where they transport potassium ions out of cells.

About Pairnomix
Pairnomix™, a personalized genetic evaluations company, is committed to helping people living with rare diseases understand the genetic cause of their condition and explore potential treatment options that are available today. Pairnomix' initial focus is on advancing personalized research for people living with epilepsy and other disorders of the Central Nervous System. To learn more, please visit www.pairnomix.com.

 

View original content with multimedia:http://www.prnewswire.com/news-releases/kcnq2-cure-alliance-extends-collaboration-with-pairnomix-to-provide-genetic-evaluation-services-for-patients-with-rare-genetic-epileptic-encephalopathy-300491333.html


'/>"/>
SOURCE Pairnomix, LLC
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Asymmetrex Presents Adult Tissue Stem Cell Counting at the Alliance for Regenerative Medicine’s First Partnering Conference, May 22-23
2. Enzo Biochem Partnering Deals and Alliances 2010 to 2017
3. University of Pittsburgh and Bayer Form Alliance to Advance Research for New Therapies for Heart, Lung and Blood Diseases
4. Inflamax Research Expands to the EU in Strategic Alliance with the Vienna Challenge Chamber
5. Massachusetts General Hospital Enters Into a Technology Alliance Partnership with IntelliCyt for the Development of CRISPR Functional Screening Applications
6. QIAGEN Forms Lung Cancer Expert Alliance
7. Global Stem Cells Group and Kimera Labs Announce Autologous Stem Cell Research Alliance
8. Interventional Concepts and ACRES Announce Alliance for Colombia
9. Aptuit et Icagen concluent une alliance stratégique
10. WuXi and AstraZeneca Form Strategic Alliance to Expedite Development of AstraZenecas Innovative Biologics Portfolio in China
11. HUYA Bioscience International Announces A Strategic Alliance With The Korea Drug Development Fund
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/14/2017)... ... September 14, 2017 , ... ... of its CliniControl™ (CC) product portfolio, clinically-relevant starting and ancillary materials that ... human Mesenchymal Stem/Stromal Cell (hMSC)-based therapies. The CliniControl product portfolio will radically ...
(Date:9/14/2017)... , ... September 14, 2017 , ... One of the ... Saturday, Sept. 16. , For six hours that day, the GenCure Marrow Donor Program ... more than 30 H-E-B grocery stores in San Antonio. , The registration tables will ...
(Date:9/13/2017)... ... September 13, 2017 , ... AMRI, a global contract ... patient outcomes and quality of life for more than 25 years, today announced ... expert to the International Standards Organization/Technical Committee 194: Biological and Clinical Evaluation ...
(Date:9/12/2017)... ... September 12, 2017 , ... Avomeen.com, the analytical ... and development companies will be exhibiting at the 16th annual Contract Pharma Conference ... Pharma is an educational conference for pharma and bio-pharma professionals that has ...
Breaking Biology Technology:
(Date:4/11/2017)... PALM BEACH GARDENS, Fla. , April 11, ... biometric identity management and secure authentication solutions, today ... million contract by Intelligence Advanced Research Projects Activity ... technologies for IARPA,s Thor program. "Innovation ... the onset and IARPA,s Thor program will allow ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
(Date:4/5/2017)... 5, 2017 Today HYPR Corp. , ... server component of the HYPR platform is officially ... end-to-end security architecture that empowers biometric authentication across Fortune ... already secured over 15 million users across the financial ... connected home product suites and physical access represent a ...
Breaking Biology News(10 mins):